Clinical trial
PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or…
NCT00048230 · Millennium Pharmaceuticals, Inc., Industry · Completed
Key facts
| NCT number | NCT00048230 |
|---|---|
| Title | PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma |
| Official title | An International, Multi-Center, Randomized, Open-Label Study of PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma |
| Lead sponsor | Millennium Pharmaceuticals, Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | bortezomib |
| Enrollment | 620 |
| Start date | Jun 1, 2002 |
| Primary completion | Jul 1, 2004 |
| Completion | Dec 1, 2004 |
| First posted | Oct 30, 2002 |
| Last update posted | Jan 13, 2012 |
| Countries | Austria, Belgium, Canada, France, Germany, Ireland, Israel, Italy, Netherlands, Spain, Sweden, United Kingdom and 1 more |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: